We envision a new age in healthcare, wherein a single highly multiplexed, multi-analyte assay with single-cell sensitivity not only replaces thousands of targeted diagnostics for individual cancers, infectious diseases, metabolic conditions and other rare or common disorders; but also, generates actionable individualized information to streamline clinical intervention strategies. Using a modular platform, MYi has the technology to analyze hundreds of molecules in a drop of blood, where those molecules are both identified and quantified using a consumer next-generation sequencing device. The obtained molecular information can be ported to a medical professional and then rerouted to the consumer as a medically curated report. As we leverage the multiplex and high-throughput nature of next-generation sequencing, we can analyze hundreds of different samples in parallel, drastically minimizing costs. With far reaching applications in cancer diagnostics, blood analyses, early disease detection, and precision medicine the potential for MYi to revolutionize medicine is high.
You might also be interested in
No Offer, Solicitation, Advice, or Recommendation
Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities.